The transforming ability of oncogenic K-Ras and activated Raf kinase has been eliminated by conditional ICMT deletion, and inhibitors of ICMT enzymatic activity have shown promising activity in both a variety of cancer cell lines in vitro and human cancer xenograft models in vivo1. The gene discussed is KRAS; the disease is cancer.